Vivos Therapeutics Inc (VVOS)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.29M
Last updated: Nov 17, 2026 at 4:14 PM ET
Vivos Therapeutics Inc (VVOS) Statistics
Vivos Therapeutics (VVOS) has a market cap of $3.29M and an enterprise value of $8.06M. Its share count is up 141.97% from a year earlier. It kept -108.11% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 144.70% above the market cap, as debt exceeds cash.
| Market Cap | $3.29M |
|---|---|
| Enterprise Value | $8.06M |
| Latest price (Nov 17, 2026) | $0.08 |
Key Dates
The next earnings report is expected on Apr 13, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Apr 13, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.1x and 0.9x.
| P/S Ratio | 0.1x |
|---|---|
| Forward P/S | 0.2x |
| P/B Ratio | 0.9x |
Price Statistics
The stock is down 96.59% over 52 weeks and trades 42.86% below its 50-day average.
| Beta (1Y) | 1.63 |
|---|---|
| 52-Week Change | -96.59% |
| 1-Month Change | -40.92% |
| 3-Month Change | -71.09% |
| 6-Month Change | -86.38% |
| 5-Year Change | -99.87% |
| Total Return (1Y) | -96.59% |
| Total Return (3Y CAGR) | -72.97% |
| Total Return (5Y CAGR) | -74.49% |
| Max Drawdown (1Y) | -96.85% |
| Max Drawdown (3Y) | -99.81% |
| Sharpe Ratio (1Y) | -3.48 |
| Correlation with SPY (1Y) | 0.23 |
| 50-Day Average | $0.14 |
| 200-Day Average | $0.64 |
| 52-Week Range | $0.07 to $2.69 |
| RSI (14 Days) | 26.0 |
| Average Volume (20 Days) | 1.22M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.22x current liabilities, and total debt is 2.12x shareholder equity.
| Current Ratio | 0.22x |
|---|---|
| Quick Ratio | 0.22x |
| Debt / Equity | 2.12x |
Returns and Efficiency
Return on invested capital is -237.85% and return on equity is -940.59% over the last 12 months.
| Return on Equity (ROE) | -940.59% |
|---|---|
| Return on Assets (ROA) | -97.12% |
| Return on Invested Capital (ROIC) | -237.85% |
| Return on Capital Employed (ROCE) | -331.66% |
| Asset Turnover | 0.85x |
| Receivables Turnover | 10.78x |
Scores
VVOS has an Altman Z-Score of -11.51, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -11.51 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue of $20.53M over the last 12 months is up 18.57% from the 12 months before.
| Revenue | $20.53M |
|---|---|
| Revenue Growth (YoY) | +18.57% |
| Gross Profit | $12.31M |
| Operating Income | -$21.71M |
| Pretax Income | -$22.20M |
| Net Income | -$22.20M |
| EBITDA | -$20.24M |
| EBIT | -$22.20M |
| Reported EPS (TTM) | -$1.48 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 10.32% of the $22.86M in total assets.
| Cash and Equivalents | $247.00K |
|---|---|
| Total Debt | $5.01M |
| Net Debt | $4.77M |
| Net Debt Per Share | $0.18 |
| Working Capital | -$12.65M |
| Shareholder Equity | $2.36M |
| Book Value Per Share | $0.09 |
| Tangible Book Value | -$9.65M |
| Total Assets | $22.86M |
| Total Liabilities | $20.69M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $7.21M of capital spending, operating cash flow left -$23.36M of free cash flow.
| Operating Cash Flow | -$16.15M |
|---|---|
| Capital Expenditures | $7.21M |
| Free Cash Flow | -$23.36M |
| FCF Per Share | -$0.69 |
| Depreciation and Amortization | $1.96M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -105.75%.
| Gross Margin | 59.96% |
|---|---|
| Operating Margin | -105.75% |
| Pretax Margin | -108.11% |
| Net Margin | -108.11% |
| EBITDA Margin | -98.58% |
| EBIT Margin | -108.11% |
| FCF Margin | -113.76% |
| Gross Margin (5Y Average) | 63.51% |
Growth
Revenue grew 2.87% a year over 3 years.
| Revenue Growth (3Y CAGR) | +2.87% |
|---|---|
| Revenue Growth (5Y CAGR) | -7.77% |
Dividends and Yields
VVOS does not pay a dividend. Its free cash flow yield is -1104.71%.
| FCF Yield | -1104.71% |
|---|---|
| Buyback Yield | -204.51% |
| Shareholder Yield | -204.51% |
Stock Splits
The last split was a 1-for-25 reverse split on Oct 27, 2023.
| Last Split Date | Oct 27, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:25 |
Peer Position
Against 6 similar companies, VVOS has the lowest P/S and the 6th highest ROIC.
P/S RatioPeer median 0.6x
ROICPeer median -65.64%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +36.55%
| P/S Ratio | 0.1x vs 0.6x median |
|---|---|
| ROIC | -237.85% vs -65.64% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +18.57% vs +36.55% median |
Analyst Forecast
Consensus estimates put revenue growth at 39.79% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +39.79% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VVOS
What is VVOS's market cap?
Vivos Therapeutics has a market cap of $3.29M. Its enterprise value, which adds debt and subtracts cash, is $8.06M.
How many shares of VVOS are outstanding?
Vivos Therapeutics has 26.53M shares outstanding. The count is up 141.97% from a year earlier.
Does VVOS pay a dividend?
No. Vivos Therapeutics does not pay a dividend.
How much debt does VVOS have?
Vivos Therapeutics has $5.01M of total debt and $247.00K of cash and equivalents, a net debt position of $4.77M.
VVOS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors